A PYMNTS Company

UK: Pfizer and Flynn accused of overcharging

By  |  August 9, 2015

Pfizer and Flynn Pharma are under investigation amid claims they charged “excessive and unfair” prices for a widely-used epilepsy drug in the UK.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The probe by the Competition and Markets Authority is focusing on phenytoin sodium, a drug that has been used to treat epilepsy for decades, which is manufactured by Pfizer but sold in the UK by Flynn Pharma.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    It is estimated that around 50,000 people in the UK take phenytoin to control tonic-clonic and focal seizures caused by epilepsy as well as those caused by head trauma or brain surgery.

    Pfizer’s brand name for the drug in the UK was Epanutin and according to the CMA the NHS spent around £2.3m on the drug before it sold the UK distribution rights to Flynn Pharma in 2012, which promptly de-branded the product.

    Full content: Mail Online

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.